Tamoxifen, balancing risks and benefits.
Bergman
L
L
Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Benraadt
J
J
van Leeuwen
F E
FE
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D016889:Endometrial Neoplasms / Q000453:epidemiology*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D012306:Risk; D013629:Tamoxifen / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen